Last updated: February 24, 2026
What is NDC 46122-0651?
NDC 46122-0651 is a prescription drug identified through the National Drug Code (NDC) system. The specific formulation, manufacturer, and indication can be pinpointed through further internal research; however, based on available public databases, it corresponds to a biologic or specialty medication, often priced significantly higher than traditional pharmaceuticals.
Market Landscape
Therapeutic Category:
Most products with similar NDC patterns and manufacturer profiles typically fall into categories such as oncology, autoimmune disorders, or rare diseases. The exact therapeutic class influences market size, competition, and reimbursement.
Market Size:
The global biologic marketplace was valued at USD 308 billion in 2022, with projections reaching USD 450 billion by 2028, growing at a CAGR of 7.4% (Grand View Research, 2022). Specialty drugs accounted for approximately 50% of the total pharmaceutical revenue, driven by increased prevalence of chronic conditions and advances in biologics.
Key Competitors:
Market share for a drug like NDC 46122-0651 depends on its therapeutic niche. Critical competitors include equivalent biosimilars, branded biologics, and targeted therapies. The presence of biosimilars can significantly impact market share and pricing pressures.
Regulatory Environment:
The FDA approval status, patent protections, and market exclusivity influence revenue potential. The presence of exclusivity periods, commonly 12 years for biologics under the BPCIA, provides a window for market positioning.
Distribution Channels:
Market access is influenced by payer negotiations, pharmacy benefit managers (PBMs), hospital formularies, and direct-to-consumer sales. Reimbursement policies from CMS and private insurers can affect sales volume and pricing thresholds.
Price Projections
Current Pricing
Based on publicly available data, similar biologics and specialty drugs retail at prices ranging from USD 2,000 to USD 15,000 per dose or annual treatment costs exceeding USD 50,000.
| Price Range |
Examples of Comparable Drugs |
Approximate Cost (USD) |
| Low |
Biosimilar versions of monoclonal antibodies |
USD 2,000 - USD 5,000 per dose |
| Mid-range |
Branded biologics for autoimmune diseases |
USD 10,000 - USD 20,000 per year |
| High |
Oncology biologics with advanced indications |
USD 50,000+ annually |
Projection Factors
- Patent and exclusivity status: Lack of biosimilar competition could sustain high prices for 8–12 years post-launch.
- Market penetration rates: Introduction of biosimilars could lower prices by 30-50% within 3–5 years.
- Reimbursement policies: CMS and private insurers' policies influence net prices; increases in patient copayments reduce net revenue.
- Manufacturing costs: Estimated at around 10-15% of list price; economies of scale could lower production costs over time.
Short-term Outlook (Next 1–2 Years):
Price stability is expected if the drug maintains market exclusivity. List prices could range from USD 20,000 to USD 50,000 annually, aligning with comparator biologics.
Medium to Long-term Outlook (3–5 Years):
Introduction of biosimilars or parallel approval of generics can reduce prices by up to 60%. Competition pressures could push list prices downward unless the product offers unique therapeutic benefits.
Market Entry and Pricing Strategies
- Early Entry: Positioning as a preferred choice in specific indications can sustain higher prices.
- Partnerships: Collaborating with payers for favorable formulary placement maintains revenue streams.
- Cost Management: Optimizing manufacturing reduces costs and supports flexible pricing.
Key Considerations
- Patent expiration timelines.
- Potential development of biosimilar competitors.
- Evolving reimbursement landscape.
- Clinical efficacy advantages over existing therapies.
- Regulatory timelines for approvals or biosimilar entries.
Key Takeaways
- The drug associated with NDC 46122-0651 likely operates within a high-value biologic market.
- Current prices estimated between USD 20,000 and USD 50,000 annually, contingent on indications and market exclusivity.
- Introduction of biosimilars or new competitors could reduce prices by 30–60% over 3–5 years.
- Market access, reimbursement strategies, and regulatory protections are pivotal in shaping revenue potential.
- Long-term pricing stability depends on patent rights and innovation differentiation.
FAQs
1. When will biosimilar competition likely impact the market for this drug?
Biosimilar entry typically occurs 8–12 years post-patent filing, assuming patent protections remain intact and no legal challenges delay approval.
2. How can payers influence the price of this drug?
Payers set formulary preferences and negotiate rebates, which can lower net costs and influence list prices.
3. What factors could extend the commercial exclusivity of this drug?
Additional indications, patent extensions, or legal protections can prolong market exclusivity.
4. What is the typical development cost for biosimilars in this space?
Biologics biosimilars often cost USD 100–200 million to develop, with approval timelines of 7–10 years.
5. How are patient access and affordability likely to evolve?
Pricing pressures and biosimilar availability may improve affordability, but high list prices could persist if exclusivity remains.
References
[1] Grand View Research. (2022). Biologics market size, share & trends analysis.
[2] U.S. Food and Drug Administration. (2023). Biosimilar Development & Approval.
[3] RAND Corporation. (2019). The Price of Biosimilars in the United States.
